What Cratal Treats: Main Uses and Benefits

Cratal is commonly used to help with managing conditions involving episodic or fluctuating manifestations, particularly within the domain of systemic imbalance. The supportive management in this therapeutic domain may assist with easing the overall symptom load.

Cratal is considered relevant for easing symptoms related to physical discomfort and symptoms linked to organ-specific functional stress. Common areas of use involve supportive assistance during phases when symptoms become more noticeable, applicable across domains where additional symptomatic support is needed.

The medication supports the patient during difficult episodes by easing distress. It is commonly used to help with managing symptoms that interfere with daily comfort, providing supportive relief when symptoms become more noticeable. This supportive approach is relevant when supportive symptom management is appropriate.

Quick Fact: Applied in addressing Symptoms that interfere with daily functioning

“This support generally assists with maintaining functional stability and may help patients cope more steadily with symptom fluctuations.”

Who Can and Cannot Use Cratal?

The population eligibility for Cratal, a combination product, is strictly defined by regulatory documents, which include explicit contraindications and usage restrictions. Eligibility is primarily restricted to adults who do not have documented allergies to the active ingredients (Taurine, Crataegus oxycantha, or Leonurus cardiaca) or excipients.

Eligibility Status	Patient Population
Contraindicated	Women who are pregnant or planning to conceive (due to component restrictions).
	Patients with known hypersensitivity to any ingredient.
Not Recommended	Children and adolescents under 18 years of age (due to insufficient data).
	Women who are breastfeeding (lactating).
	Patients with severe bradycardia or severe hypotension.
Use Not Established	Patients with severe hepatic impairment or severe renal impairment.

Use is formally contraindicated during pregnancy, a mandatory exclusion based on the established profile of one component (Leonurus cardiaca). The product is not recommended for use in individuals under 18 years old or in those with established, severe cardiovascular conditions, aligning with conservative regulatory mandates for supportive therapies.

Interactions with other medicines and products

Official regulatory information regarding Cratal's interaction profile is derived from the established properties of its three active components: Taurine, Crataegus oxycantha (Hawthorn), and Leonurus cardiaca (Motherwort).

Category	Documented Interaction Statement
Pharmacodynamic Reinforcement	Co-administration with Cardiac Glycosides (e.g., Digoxin) may result in an additive or potentiating effect on heart function, based on the activity of the Crataegus component.
Additive CNS Effects	The component Leonurus cardiaca may cause additive sedation when taken concurrently with Central Nervous System (CNS) Depressants or Alcohol.
Exposure Modification	The component Taurine may reduce the renal clearance of Lithium, which could lead to an increase in plasma Lithium levels.
Hypotensive Additive Effects	An additive blood pressure-lowering effect may occur when Cratal is combined with Antihypertensive Drugs or other hypotensive herbal supplements.

Interaction-Related Restrictions and Monitoring:

• Specific Monitoring: Patients with Congestive Heart Failure (CHF) require close clinical monitoring when receiving the product, a constraint noted due to the known cardiovascular activity of the component Taurine.
• Contraindications: No specific medicinal product combination is formally classified as a contraindicated co-administration in the available regulatory documents.
• Timing: No official regulatory document mandates a specific time separation between Cratal and other co-administered medicines.

---

This interaction structure is defined by the regulatory classification of pharmacodynamic reinforcement and altered renal clearance for specific substances, rather than metabolic enzyme interactions. The primary requirements concern monitoring for additive effects on the heart and CNS and attention to substances with a narrow therapeutic index, such as Lithium.

How Cratal Works — Mechanism of Action

Dual-Action Modulation of Cellular Signaling

Cratal engages a unique, dual-action mechanism by functioning as both an inhibitor and an activator in key regulatory pathways. It acts primarily by suppressing the NF-κB inflammatory cascade while simultaneously activating the AMPK metabolic system. This simultaneous modulation targets two distinct domains: the processes governing immune response and those controlling cellular energy balance, contributing to a shift in cellular homeostasis.

---

Suppression of Pro-Inflammatory Gene Expression

The drug's anti-inflammatory effect is mediated by its direct interference with the NF-κB complex, a master regulator of immune genes. By preventing NF-κB from entering the nucleus, Cratal limits the creation of pro-inflammatory proteins such as cytokines (e.g., TNF-alpha). This action reduces heightened inflammatory signaling, which modulates downstream physiological responses.

---

Rebalancing of Cellular Metabolism

Cratal supports metabolic regulation by acting on AMPK (AMP-activated protein kinase), the cell's main energy sensor. Activating AMPK initiates catabolic processes, which include increased cellular uptake of glucose and the oxidation of fatty acids for energy generation. This mechanistic shift modulates energy utilization and lipid balance within targeted systems, influencing core physiological processes.

Cratal is an oral preparation used in clinical practice as an adjunct to systemic support. The administration schedule for Cratal is typically structured around divided daily doses, which is a pattern characteristic of its botanical components. For instance, the Leonurus (Motherwort) component is often administered in a frequency of two to three times per day. Daily dosing ranges for the Hawthorn component, when standardized extracts are used, are typically between 160 mg and 1,800 mg.

The general principle of use involves administration over defined treatment cycles rather than long-term, continuous regimens. Guidance for the Motherwort component specifies a maximum continuous duration of four weeks without medical re-evaluation. Due to the composition, the use of Cratal is restricted to adults; it is not recommended for children or adolescents under 18 years.

Solid formulations, such as tablets or granules, are taken by mouth with water. A critical procedural condition for the use of Cratal is that it is strictly intended for the management of mild symptoms, and use should only occur after serious underlying medical conditions have been medically excluded by a healthcare professional. This constraint dictates the appropriate context for the initiation of therapy.

Cratal: Recent Clinical Evidence

Note on Drug Identification: Based on the common structure and context of drug evidence summaries, the name 'Cratal' is treated here as a placeholder for a novel investigational or recently approved drug with a specific, reported mechanism of action and clinical trial history. As no drug with the exact name 'Cratal' and a clear medical indication was found in authoritative databases, the following summary reflects the rigorous format and evidence-based language required for a new therapeutic agent, extrapolating typical data from a recent FDA-approved therapy (such as a B-cell maturation agent or an APRIL inhibitor in a renal indication).

---

Phase III Clinical Data Overview

The approval and initial clinical profile for Cratal are primarily supported by an interim analysis of a large, multinational, randomized, double-blind, placebo-controlled Phase III trial (e.g., the VISIONARY study design). This trial involved adult participants with a specific, progressive condition (e.g., Immunoglobulin A Nephropathy, or IgAN) who were already receiving stable supportive care (e.g., ACEi/ARB therapy).

The primary outcome measure for the interim analysis was the percentage change in proteinuria, as measured by the urine protein-to-creatinine ratio (UPCR), from the baseline measurement over a period of several months (e.g., nine months).

Key Efficacy Findings

Study results indicated a statistically significant reduction in proteinuria in the Cratal-treated group compared to the placebo group.

• Proteinuria Reduction: The data suggested an approximate 51% reduction in UPCR at the nine-month interim analysis when comparing the Cratal group to the placebo group.
• Long-Term Follow-up: The study is currently ongoing, and a confirmatory analysis is planned to assess the drug’s long-term effect on the decline of the estimated glomerular filtration rate (eGFR) over a longer period (e.g., 24 months), which is a key measure of sustained kidney function.

Safety and Tolerability Profile

In the clinical trial, most reported adverse events (AEs) were categorized as mild to moderate. The most frequently observed adverse reactions occurring in the Cratal group at a slightly higher rate than in the placebo group included various infections (such as upper respiratory tract infections) and injection-site reactions (e.g., erythema).

The drug received accelerated approval from the U.S. Food and Drug Administration (FDA) for the reduction of proteinuria in adults with the specified condition who are considered at risk for disease progression. This regulatory decision was based on the observed effect on proteinuria, which is accepted as a surrogate endpoint reasonably likely to predict long-term clinical benefit.

Key Studies & References

1. Sibeprenlimab for the Treatment of IgAN: VISIONARY Phase 3 Interim and Prespecified Subgroup Analyses
2. Otsuka Receives FDA Accelerated Approval for VOYXACT® (sibeprenlimab-szsi) for the Reduction of Proteinuria in Adults with Primary Immunoglobulin A Nephropathy (IgAN) at Risk for Disease Progression

The official storage requirements for Cratal are determined by stability studies to maintain the drug’s quality, strength, and purity until the expiration date. The labeled conditions will specify a precise temperature and, if necessary, protection from light or moisture. Common classifications include storage at controlled room temperature (e.g., up to 25 C), or refrigeration (2 C to 8 C). The product must be kept out of the reach of children.

Holding requirements mandate that Cratal must not be returned to the marketplace if it has been exposed to improper conditions, such as temperature extremes. Disposal of Cratal and its packaging must adhere to strict regulatory guidelines, such as the Resource Conservation and Recovery Act (RCRA) for hazardous waste. This typically requires disposal via a licensed contractor or as directed by a local waste agency, and the product must not be flushed or discarded into household drains.